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OBJECTIVE—Short sleep duration is associated with impaired
glucose tolerance and an increased risk of diabetes. The effects
of sleep restriction on insulin sensitivity have not been estab-
lished. This study tests the hypothesis that decreasing nighttime
sleep duration reduces insulin sensitivity and assesses the effects
of a drug, modaﬁnil, that increases alertness during wakefulness.
RESEARCH DESIGN AND METHODS—This 12-day inpatient
General Clinical Research Center study included 20 healthy men
(age 20–35 years and BMI 20–30 kg/m
2). Subjects spent 10
h/night in bed for 8 nights including three inpatient nights
(sleep-replete condition), followed by 5 h/night in bed for 7
nights (sleep-restricted condition). Subjects received 300 mg/day
modaﬁnil or placebo during sleep restriction. Diet and activity
were controlled. On the last 2 days of each condition, we
assessed glucose metabolism by intravenous glucose tolerance
test (IVGTT) and euglycemic-hyperinsulinemic clamp. Salivary
cortisol, 24-h urinary catecholamines, and neurobehavioral per-
formance were measured.
RESULTS—IVGTT-derived insulin sensitivity was reduced by
(means  SD) 20  24% after sleep restriction (P  0.001),
without signiﬁcant alterations in the insulin secretory response.
Similarly, insulin sensitivity assessed by clamp was reduced by
11  5.5% (P  0.04) after sleep restriction. Glucose tolerance
and the disposition index were reduced by sleep restriction.
These outcomes were not affected by modaﬁnil treatment.
Changes in insulin sensitivity did not correlate with changes in
salivary cortisol (increase of 51  8% with sleep restriction, P 
0.02), urinary catecholamines, or slow wave sleep.
CONCLUSIONS—Sleep restriction (5 h/night) for 1 week sig-
niﬁcantly reduces insulin sensitivity, raising concerns about
effects of chronic insufﬁcient sleep on disease processes associ-
ated with insulin resistance. Diabetes 59:2126–2133, 2010
T
he average sleep duration in the U.S. has fallen
below 7 h per night, a drop of 2 h per night over
the last century and 1 h per night over the last
40 years (1,2). Cross-sectional and longitudinal
studies have demonstrated a link between short sleep
duration or poor sleep quality and increased risk of obesity
(3–7), diabetes (7–11), hypertension (12), cardiovascular
disease (13,14), the metabolic syndrome (15), and early
mortality (14,16–21). Short-term sleep restriction (4
h/night for 1 week in a laboratory setting) impaired
glucose tolerance during a frequently sampled intravenous
glucose tolerance test (IVGTT) in healthy subjects (22).
In healthy subjects, the mechanisms leading to impaired
glucose tolerance with short-term reductions in nightly
sleep duration are unclear. Decreases in insulin secretion
have been implicated, and sleep restriction increases
cortisol levels, which could inﬂuence glucose tolerance
(22). Further, insulin resistance has been reported in two
very different models of disrupted sleep: sleep apnea (23)
and experimental disruption of slow-wave sleep (24). In
the latter model, the extent of slow-wave sleep disruption
predicted reductions in insulin sensitivity (24).
Our primary goal was to test the hypothesis that sleep
restriction in healthy subjects reduces insulin sensitivity
as assessed by the hyperinsulinemic-euglycemic clamp.
Insulin secretion was assessed using IVGTTs. To identify
possible mechanisms by which sleep restriction may affect
insulin sensitivity, we assessed the relationships between
changes in insulin sensitivity and changes in cortisol,
catecholamines, and slow-wave sleep. Further, we tested
the ability of modaﬁnil to ameliorate the adverse effects of
sleep restriction on insulin sensitivity. Modafanil activates
central, wake-promoting dopaminergic and noradrenergic
mechanisms (25,26) and ameliorates the adverse effects of
sleep deprivation on alertness and performance (27–29)—
impairments that have been attributed to reduced brain
glucose utilization (30). Thus, we performed hyperinsu-
linemic-euglycemic clamps and intravenous glucose toler-
ance twice: at baseline in sleep-replete individuals and
after 7 nights of sleep restriction (5 h in bed) in healthy
individuals randomized to daily treatment with placebo or
modaﬁnil.
RESEARCH DESIGN AND METHODS
A schematic of this double-blind, placebo-controlled, randomized, clinical
study is presented in Fig. 1. Procedures were approved by the Human
Research Committee of the Brigham and Women’s Hospital and conducted
according to the principles expressed in the Declaration of Helsinki. All
subjects provided written informed consent.
Subject recruitment and screening. Healthy male subjects were recruited
using newspaper ads, ﬂyers, and website postings. Subjects were screened for
sleep patterns and medical and psychological history, underwent a physical
examination by a licensed physician, and provided blood and urine samples to
ensure that hematology and serum chemistry, including metabolic and thyroid
panels, were within normal limits. All subjects passed a urine toxicology
screen.
Prestudy conditions. Before the experiment, subjects slept at home for at
least 5 days (mean 8.9 days [range 5–21]) with 10 h per night of time in bed
(TIB) from 10 P.M.t o8A.M.( 1 h) in order to enter the experimental portion
of the protocol in a nearly sleep-replete state, i.e., with similar and presumably
minimal amounts of sleep debt (31). Subjects called into a time-stamped
phone-answering system, wore wrist activity monitors (Minimitter, Bend, OR)
and completed a sleep diary to assure compliance with this schedule.
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Research Center at Brigham and Women’s Hospital for a 12-day inpatient visit.
The study began with a 3-day baseline period of 10/h night TIB (continued
from the pretest period) and baseline metabolic assessments, after which
subjects were scheduled for sleep restriction (5 h/night TIB) for the following
7 nights, with the sleep periods centered at the same clock time of 0300 h.
During the periods of wakefulness, subjects were allowed to perform activi-
ties such as writing, reading, computer work, board or card games, movie
viewing, arts and crafts, listening to or playing music, and light stretching.
Subjects were observed by research technicians throughout the protocol
either through direct interaction or remotely via video. Light levels during
sleep periods were essentially complete darkness (1 lux) and 90 lux during
wakefulness, which simulations suggest would lead to a 9 min mean
difference of circadian phase between sleep conditions (32). Subjects were
randomized to modaﬁnil (100 mg per tablet) or placebo (two tablets at 0600 h
and one tablet at 1300 h) during the 7 days of sleep restriction. Post–sleep
restriction metabolic assessments were performed, and subjects were dis-
charged on day 12 after a recovery night of 10 h TIB (Fig. 1). Metabolic
assessments are described below and consisted of an IVGTT, euglycemic-
hyperinsulinemic clamp, and collection of saliva and urine for hormone
measurements. During each sleep period, scalp surface electrodes (Beckman
Instrument Company, Schiller Park, IL) were applied to speciﬁc locations on
the subject’s face and scalp at least 2 h prior to the scheduled sleep period for
recordings of central (C3 and C4) and occipital (O1 and O2) electroencepha-
logram, electrooculogram, electromyogram, and electrocardiogram. Data
were collected using Vitaport Three digital sleep recorders (TEMEC) and
scored visually in 30-s epochs by registered polysomnographic technologists
(33).
Controlled diet. Throughout the inpatient portion of the study, subjects
received an isocaloric, controlled-nutrient diet containing 58–60% carbohy-
drates, 15–17% protein, 25–27  1% fat , 800–1,000 mg calcium, 100 2 mEq
potassium, and 200 2 mEq sodium. Subjects were required to consume all
food provided. An identical menu was provided on the day before and the day
of each IVGTT and each euglycemic-hyperinsulinemic clamp procedure.
Subjective measures of sleepiness and alertness. Every 3 hours during
wake periods, subjects completed a short test battery including the Karolinska
Sleepiness Scale (34) and the Psychomotor Vigilance Task (PVT) (3,24). The
Psychomotor Vigilance Task involved a 10-min visual reaction time perfor-
mance test in which the subject was instructed to maintain the fastest possible
reaction time to a simple visual stimulus. Lapses of attention refer to the
number of times the subject failed to respond to the signal within 500 ms.
Frequently-sampled IVGTT (insulin modiﬁed). IVGTT tests were per-
formed after an overnight fast on the mornings of days 3 and 10, e.g., following
the penultimate night of 10 h TIB and the penultimate (sixth) night of 5 h TIB,
respectively. Blood samples were drawn via an intravenous catheter every 5
min for 20 min starting at T  20 min. At time 0 (9 A.M.), 0.3 g/kg glucose was
infused over 1 min via an intravenous catheter in the nonsampling arm. Blood
samples were then taken at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16 19, 21, 22, 24, 26, 28,
30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, and 180 min. At time 20
min, 0.02 units/kg human insulin (Novolin R U-100; Novo Nordisk, Princeton,
NJ) was administered intravenously in 30 s, including saline ﬂush. Minimal
model analyses (Minmod Millennium 2000; R. Bergman, University of South-
ern California, Los Angeles, CA) were performed to determine ﬁrst-phase area
under the insulin curve from 0 to 10 min, glucose effectiveness and insulin
sensitivity (SI). Glucose tolerance was calculated as the slope of the natural
log of glucose values from minute 5 to minute 19.
Euglycemic-hyperinsulinemic clamp procedure. Insulin sensitivity was
measured using the insulin clamp procedure as previously described (35).
Studies were performed on the mornings of days 4 and 11, following the ﬁnal
night of 10 h TIB and the ﬁnal (seventh) night of 5 h TIB, respectively.
Following an overnight fast, the subject remained in bed until the completion
of the procedure. Intravenous lines were placed in each arm for infusion or
blood draw. After a baseline sample was collected, subjects were infused with
human insulin (Novolin R) with priming doses of 80 and 60 mU/m
2 body
surface area per min over the ﬁrst two 5-min periods, respectively, followed by
a constant infusion rate of 40 mU/m
2 per min for 170 min. Blood samples were
collected every 5 min from T  0 to 180 min from a catheter placed retrograde
in a dorsal vein of the wrist; this hand was placed in a hand warmer
thermostatically controlled at 140°F to arterialize venous blood. Serum
glucose levels were determined immediately at the bedside, and serum insulin
was measured from frozen samples. Dextrose solution (20%) was variably
infused to maintain serum glucose levels at 90 mg/dl throughout the clamp
procedure. The mean dextrose infusion rate over the last 60 min of the clamp
(M), after correcting for changes in plasma glucose concentration [expressed
as mg (glucose)  kg
1 body weight  min
1 of infusion] as described by
Defronzo et al. (36), was determined and used as an indicator of insulin
sensitivity.
Resting metabolic rate. Raising metabolic rate (RMR) was estimated from
expired gases using a validated and FDA-approved indirect calorimeter
(Medgem 100; Healthetech) that estimates RMR in kilocalories per day (20,37).
Assessments were made upon waking in the sleep-replete condition while
subjects were still in bed (i.e., after a 12-h fast) after a void and at least 10 min
of quiet bed rest. The timing was at the same clock time in both conditions,
0820 h, and the test duration was 12–14 min until steady state was
attained.
Saliva and urine sampling. Saliva samples for determination of free cortisol
levels were collected from 1500 to 2100 h on the last 2 days of each condition.
Twenty-four hour urine collections were obtained on the last 2 days of each
condition.
Assays. Serum glucose during the clamp studies was measured using the
Beckman Glucose Analyzer 2 (Beckman Coulter, Chaska, MN) with sensitivity
of 10 mg/dl and precision 5%. Serum glucose during the IVGTT was
measured using the COBAS Integra 400 (Roche Diagnostics, Indianapolis, IN)
with sensitivity of 0.59 mg/dl and precision 4.3% (37). Serum insulin was
measured by chemiluminescence immunoassay (Access Immunoassay Sys-
tem, Beckman Coulter, Chaska, MN) with sensitivity 0.03 IU/ml, precision
5.6%. Salivary cortisol was measured using a solid-phase radioimmunoassay
(Coat-A-Count; DPC, Los Angeles, CA), with sensitivity 0.02 g/dl and
precision 4–5%. Urinary norepinephrine and epinephrine was assayed using
the LDN CAT RIA kit (Immuno Biological Laboratories, Minneapolis, MN).
The sensitivity of this method is 1.5 ng/ml for norepinephrine and 0.3 ng/ml for
epinephrine; the precision is 15% for both assays (38).
Statistical analyses. Mixed-effects models were applied to study the effects
of the number of nights of sleep restriction and the effects of drug treatment
on subjective and objective measures of sleepiness, including self-reported
sleepiness and lapses of attention, and on insulin secretion, insulin sensitivity,
admission discharge
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FIG. 1. Protocol schema. (See RESEARCH DESIGN AND METHODS for a detailed description.)
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rate. Treatment and sleep restriction status were considered ﬁxed effects, and
random intercepts were added to account for individual variation from the
group mean. Data are presented as means  SEM unless otherwise indicated.
RESULTS
Subjects. Twenty healthy men (mean  SD: age 26.8  5.2
years; BMI 23.3  3.1 kg/m
2) completed the study (11
placebo and 9 active drug). An additional three subjects
were withdrawn from the study after initiation of drug
treatment as a result of 1) transient EKG changes in one
subject, 2) tachycardia (up to 126 bpm) and elevated blood
pressure (systolic 145 mmHg and diastolic 91 mmHg) in
another subject, and 3) tachycardia (up to 127 bpm),
elevated systolic blood pressure (systolic 147 mmHg and
diastolic 87 mmHg), and urinary frequency in a third
subject. These subjects were otherwise asymptomatic.
Unblinding revealed that all three of these subjects had
been receiving modaﬁnil. All signs and symptoms resolved
within a day of stopping the medication.
Subjective and objective measures of sleepiness.
Sleep restriction increased self-reported sleepiness and
objective measures of sleepiness compared with the sleep-
replete baseline condition (Table 1 and Fig. 2); modaﬁnil
treatment signiﬁcantly reduced the deleterious effects of
sleep restriction on these measures of sleepiness.
Cortisol and norepinephrine. Salivary cortisol levels
(assessed between 1500 and 2100 h) were elevated with
sleep restriction compared with the baseline sleep-replete
condition (Fig. 3). The mean increase in cortisol of 0.054 
0.01 ng/ml with sleep restriction and placebo was similar
to the increase observed with sleep restriction and modaﬁ-
nil treatment (0.066  0.01 ng/ml; P  0.48). Compared
with placebo, modaﬁnil treatment signiﬁcantly increased
urinary epinephrine and norepinephrine with decreased
sleep duration (Table 1). Changes in urinary cat-
echolamines (sleep restricted  baseline sleep replete)
were 4.98  4.02 g/day (placebo [t test P  0.24]) and
18.29  3.31 g/day (modaﬁnil [t test P  0.0006]) for
norepinephrine and 1.58  1.72 g/day (placebo [t test P 
0.39]) and 6.52  0.94 g/day (modaﬁnil [t test P 
0.0001]) for epinephrine.
Energy expenditure. Fasted resting metabolic rate was
unchanged from baseline (sleep replete) to sleep restric-
tion (mean change 0  44 kcal). There were no effects of
drug treatment on the change in RMR (Table 1).
Insulin sensitivity and acute insulin response
(IVGTT). Insulin sensitivity assessed by minimal model
analysis of IVGTT data was signiﬁcantly reduced after
sleep restriction compared with the sleep-replete baseline
condition, with no signiﬁcant effect of modaﬁnil treatment
(Table 1; Fig. 4E). Fifteen out of nineteen subjects had a
decrease in SI with sleep restriction, with a mean decrease
of 20  24% (F1,18  15.18; P  0.001) (Table 1 and Fig. 4E
and F). The acute insulin response was not signiﬁcantly
affected by either sleep restriction or drug treatment
(Table 1; Fig. 4C). With sleep restriction, the disposition
index (the product of SI and acute insulin response), was
signiﬁcantly but slightly reduced (Table 1 and Fig. 4D) and
glucose tolerance was signiﬁcantly reduced (change of
0.31  0.13% per min with modaﬁnil and 0.17  0.15% per
min with placebo). There were no signiﬁcant effects of
sleep restriction or drug treatment on other minimal
model parameters (Table 1).
Insulin sensitivity (euglycemic-hyperinsulinemic
clamp). Glucose and insulin levels at baseline and during
euglycemic-hyperinsulinemic clamp protocols were simi-
lar between sleep-replete and sleep-restricted conditions
and between modaﬁnil and placebo treatments. Fasting
insulin levels were 4.5  0.4 U/ml and increased to 57.8 
2.3 U/ml during the insulin infusions. Serum glucose
TABLE 1
Sleep duration (TIB per study day) Baseline
vs. sleep
restriction
condition (P)
Drug
(P)
Interaction
(P)
Modaﬁnil Placebo
5 h1 0 h5 h1 0 h
Sleepiness: KSS (1–9 scale) 4.65  0.12 3.23  0.13 5.31  0.11 3.61  0.16 0.0001 0.0001 0.0001
Performance: PVT lapses
(lapses  test
1  day
1) 4.09  0.45 2.48  0.37 5.10  0.73 0.92  0.18 0.0001 0.008 0.002
Sleep duration: total sleep
time (min) 268.2  3.5 502.2  8.9 274.0  1.4 467.4  10.8 0.0001 0.04 0.001
Slow-wave sleep (min) 78.6  3.4 75.2  5.9 75.4  3.2 65.2  7.4 0.12 0.50 0.57
FSIVGTT
SI (mU/l)
1  min
1] 4.61  0.55 5.70  0.88 4.81  0.78 6.74  0.94 0.001 0.62 0.24
Acute insulin response
(mU  l
1  min) 549.2  127.2 514.0  106.3 532.3  94.1 566.7  112.8 0.30 0.77 0.81
Disposition index 2,034.2  231.6 2,500.6  391.9 2,079.5  254.1 2,993.7  431.6 0.02 0.46 0.52
Glucose tolerance
(%/min) 1.984  0.137 2.295  0.160 2.120  0.162 2.465  0.261 0.02 0.43 0.62
Glucose effectiveness
(min
1) 0.017  0.002 0.020  0.002 0.021  0.002 0.023  0.003 0.21 0.15 0.76
Clamp: M (mg  kg
1 
min
1) 6.15  0.66 7.11  0.86 6.95  0.81 7.39  0.79 0.05 0.55 0.69
Salivary cortisol (ng/ml) 0.179  0.017 0.112  0.013 0.180  0.015 0.125  0.010 0.0001 0.70 0.48
Catecholamines
Norepinephrine (g/day) 48.0  4.5 29.7  4.3 32.5  4.4 27.5  4.7 0.0001 0.14 0.02
Epinephrine (g/day) 13.5  1.2 7.0  0.8 9.0  2.1 7.4  1.1 0.001 0.29 0.03
Resting metabolic rate
(kcal) 1,931.4  77.4 1,928.6  79.1 1,851.0  86.4 1,853.0  116.6 0.99 0.56 0.96
Data are means  SE unless otherwise indicated.
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the clamp procedures. The dextrose infusion rate (M)
needed to maintain euglycemia during the ﬁnal hour of the
clamp procedure was signiﬁcantly reduced with sleep
restriction compared with the baseline sleep-replete con-
dition (Fig. 4G and H); there were no signiﬁcant effects of
drug treatment (Table 1). Ninety percent of subjects had
a decrease in M with sleep restriction. The mean  SE
decrease for all subjects was 11  5.5% (F1.18  4.64; P 
0.045) relative to the baseline sleep replete condition (Fig.
4). Importantly, changes in insulin sensitivity (M) assessed
by the clamp procedure correlated with the change in
insulin sensitivity (SI) assessed by the IVGTT procedure
(r  0.53; P  0.02). Overall, there was a strong correlation
of the absolute level of M with SI (r  0.85; P  0.0001).
Changes in slow-wave sleep. Sleep restriction resulted
in a signiﬁcant decrease in total sleep time, but changes in
the amount of slow-wave sleep (non–rapid eye movement
stages 3 and 4), previously linked to changes in glucose
metabolism (24), were not related to changes in insulin
sensitivity (Table 1).
Predictors of changes in insulin sensitivity. There was
not a signiﬁcant linear relationship between BMI and
change in SI (F1,17  1.04; P  0.32) or change in M
(F1,17  1.23; P  0.28), between change in cortisol
and change in SI (F1,17  1.28; P  0.27) or change in M
(F1,17  0; P  0.99), or between change in urinary
catecholamine levels and change in either Si (F1,17 
0.04, P  0.85, for norepinephrine and F1,17  1.79, P 
0.20, for epinephrine) or M (F1,17  0.68, P  0.42, for
norepinephrine and F1,17  0.01, P  0.91, for epineph-
rine). Similar results were obtained when the analysis
was restricted to subjects receiving modaﬁnil (data not
shown).
DISCUSSION
Sleep restriction to 5 h/night (TIB) for 1 week in
nonobese, healthy men signiﬁcantly reduced insulin
sensitivity as assessed by two techniques, the euglyce-
mic-hyperinsulinemic clamp and the IVGTT, yet did not
affect the acute insulin response to intravenous glucose
administration. Sleep restriction led to elevations of
afternoon and evening levels of free cortisol, but these
increases were not linearly related to changes in insulin
sensitivity. The effects of sleep restriction on measures
of glucose metabolism and on salivary cortisol were not
altered by administration of modaﬁnil, though modaﬁnil
did improve subjective and objective measures of sleep-
iness. These changes in insulin sensitivity support the
hypothesis that insufﬁcient sleep duration leads to insu-
lin resistance.
Our ﬁnding that sleep restriction leads to a decrease in
insulin sensitivity is consistent with earlier studies show-
ing impaired glucose metabolism with altered sleep dura-
tion. The earliest direct assessment of the relationship
between sleep and glucose metabolism demonstrated that
complete sleep deprivation for 3–4 days led to an elevation
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FIG. 2. Subjective sleepiness and lapses of attention under sleep
restriction conditions. Effects of sleep restriction on subjective sleep-
iness (top panel) and lapses of attention (bottom panel). Subjective
sleepiness and objective lapses of attention in sleep-replete subjects
were assessed after 10 h of TIB per night and after restricting sleep to
5 h/night over 1 week (days 1–6 averages) in subjects randomized to
placebo (red circles) or modaﬁnil administration (green triangles).
Subjective sleepiness is deﬁned as mean deviation from baseline
Karolinska Sleepiness Scale (KSS). Lapses of attention are deﬁned as
reaction times >500 ms and are quantiﬁed as the absolute deviation
from baseline (lapses/test per day). For self-reported sleepiness, we
noted signiﬁcant main effects of sleep restriction (P < 0.0001), treat-
ment (P < 0.0001), and their interaction (P < 0.0001). With modaﬁnil
administration, self-reported sleepiness was signiﬁcantly reduced com-
pared with placebo after the ﬁrst and second nights of sleep restriction
only (P  0.0276). For lapses of attention, there was a signiﬁcant main
effect of number of nights of sleep restriction (P  0.0012) and a
borderline effect for treatment (P  0.0647), and their interaction was
nonsigniﬁcant (P  0.1488). With modaﬁnil administration, lapses of
attention were signiﬁcantly reduced compared with placebo during the
daytime testing after the ﬁrst and second nights of sleep restriction
only (P  0.0141); after the second and third nights, the borderline P
values were 0.0779 and 0.0770, respectively.
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FIG. 3. Salivary (free) cortisol levels with sleep restriction. Salivary
cortisol levels were assessed hourly from 1500 to 2100 h under
sleep-replete conditions (10 h/night TIB [black circles]) and under
sleep-restricted conditions (5 h/night TIB for 1 week) in subjects
receiving placebo (red circles) or modaﬁnil (green triangles). Sali-
vary cortisol levels (means  SD) from 1500 to 2100 h were
signiﬁcantly affected by sleep duration only: 0.13  0.03 ng/ml for
the sleep-replete condition and 0.17  0.04 ng/ml for the sleep-
restricted condition (P < 0.0001 and Table 1). Identical (mixed
composition) dinners were served just after the 1800-h saliva
sample and ﬁnished before 1840 h.
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Spiegel et al. (22) from the Van Cauter laboratory per-
formed frequently sampled IVGTT (FSIVGTT) in healthy
subjects during a sleep debt condition (4 h per night) and
the sleep-replete condition (12 h/night). They found that
the sleep debt condition led to impaired glucose metabo-
lism characterized by 30–40% reductions in glucose toler-
ance, glucose effectiveness, and acute insulin response to
glucose but a nonsigniﬁcant reduction in insulin sensitiv-
ity. We also demonstrated impairment in glucose metabo-
lism with sleep restriction (to 5 h/night compared with a
baseline sleep repletion of 10 h/night), but the impairment
was attributable to a decrease in insulin sensitivity rather
than to impairments in insulin secretion or glucose effec-
tiveness. However, we did not observe a compensatory
increase in insulin secretion despite the reduction in
insulin sensitivity, so it is possible that more than one
mechanism is contributing to impaired glucose metabo-
lism with sleep restriction in our study. Our results are
consistent with recent results in 11 overweight, middle-
aged adults that sleep restriction to 5.5 h/night with an ad
libitum diet reduces insulin sensitivity but does not change
insulin secretion on an IVGTT (40). The current study
extends from these ﬁndings with two techniques for
assessing insulin sensitivity, the insulin-modiﬁed FSIVGTT
and the gold standard euglycemic-hyperinsulinemic
clamp, with concordant results. In further support of the
hypothesis that alterations in sleep may affect insulin
sensitivity, Van Cauter et al. (24) recently reported that the
nearly total suppression of slow-wave sleep by acoustic
disruption for 3 nights (without changing total sleep
duration) reduces insulin sensitivity as well as acute
insulin response.
Substantive differences in the current protocol com-
pared with the results of Spiegel et al. may account for our
different results. While both studies examined the effects
of sleep restriction in healthy subjects, the baseline sleep-
replete condition actually came after the sleep debt con-
dition in the Spiegel protocol, so the sleep-replete
condition may reﬂect more of a recovery process than the
actual baseline for each individual. We believe that our
sleep-replete baseline more accurately deﬁnes (in experi-
mental and ecological terms) the changes in both sleep
and metabolism from sleep-replete to sleep-restricted con-
ditions. In addition, the current protocol carefully con-
trolled food intake and activity, whereas the Spiegel
protocol allowed subjects to leave the laboratory each day
during sleep-restricted conditions. Also, the dose of sleep
restriction could inﬂuence the results because Spiegel et
al. restricted sleep to 4 h/night, whereas we used 5 h/night
(to apply to a greater proportion of the adult population).
Finally, the speciﬁc procedures to assess glucose metab-
olism differed between the two studies. The Spiegel study
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FIG. 4. Effects of sleep restriction on glucose metabolism. A and B:
Mean glucose levels ( SE) from IVGTT during the baseline sleep-
replete condition (10 h/night TIB [black line]) and following sleep
restriction for 1 week (5 h/night TIB) in subjects receiving placebo (A)
(red line) modaﬁnil (B) (green line). Left arrow, glucose infusion at
time  0 min; right arrow, insulin infusion at time  20 min. C and D:
Mean insulin levels ( SE) from IVGTT. E–H: IVGTT parameters were
calculated using Minmod Millennium software. Glucose and insulin
data from insulin-modiﬁed IVGTT procedures under sleep-replete
(ﬁlled symbols) and sleep-restricted conditions (open symbols) are
shown. E: Acute insulin response (AIRg) (ﬁrst phase). F: Disposition
index. G: SI from IVGTT. H: relative changes in SI from IVGTT
expressed as percent change from baseline sleep-replete condition in
subjects randomized to placebo (red circles) or modaﬁnil administra-
tion (green triangles). I: Insulin sensitivity (M) from euglycemic-
hyperinsulinemic clamp procedure. J: Relative changes in insulin
sensitivity (M) depicted as in F. There were no signiﬁcant effects of
drug administration on any metabolic parameters (Table 1).
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procedure may not have had sufﬁcient sensitivity to detect
a signiﬁcant increase in insulin resistance with sleep
restriction.
Previous studies have shown that sleep restriction in-
creases self-reported hunger and appetite for carbohy-
drate food (41,42). Therefore, to control for potential
variations in diet, subjects in the current study consumed
a consistent diet throughout the protocol. In addition,
subjects maintained a sedentary (but not bed rest) level of
activity. Thus, the current study did not allow behavioral
changes in diet composition (43), caloric intake, or activ-
ity/exercise levels that may have contributed to the asso-
ciation of reduced habitual sleep duration and metabolic
dysregulation in previous studies. We did not observe any
changes in resting metabolic rate using indirect calorime-
try, which is consistent with a prior report of a nonsignif-
icant change in total energy expenditure with sleep
restriction (42).
A further strength of the current study is that all
subjects began the study in a similar sleep-replete state
prior to the imposition of sleep restriction. Under our
experimental conditions, there was a deterioration of
subjective and objective measures of sleepiness with sleep
restriction, consistent with the known effects of sleep
restriction. Modaﬁnil administration partially mitigated
this effect. However, modaﬁnil treatment had no discern-
able affect on glucose metabolism. Activation of the hypo-
thalamic-pituitary-adrenal axis and the autonomic nervous
system are two key counterregulatory pathways for in-
creasing glucose levels during hypoglycemia. Both these
pathways also have been proposed as possible mediators
of the impairments in glucose tolerance associated with
sleep restriction (22,44–48). In the current study, sleep
restriction led to a signiﬁcant increase in salivary cortisol
and urinary norepinephrine and epinephrine. Catechol-
amine increases with sleep restriction were ampliﬁed by
modaﬁnil treatment, consistent with prior reports of in-
creased catecholamine levels with modaﬁnil administra-
tion (49). However, we found no association, under our
experimental conditions, between changes in SI and
changes in hypothalamic-pituitary-adrenal axis function
and sympathetic nervous system function, suggesting that
these systems do not mediate the changes in SI with
moderate sleep restriction.
In the present study, the relatively modest restriction of
the sleep period to 5 h per night led to a small increase in
slow-wave sleep amount by the third night, reﬂecting an
increase in homeostatic sleep drive. A study that deliber-
ately reduced slow-wave sleep through acoustic disruption
without changing total sleep time led to a reduction in SI
(24). In the current study, we observed reductions in SI
due to reductions in total sleep time—not to reductions in
slow-wave sleep. Our experimental design is much more
closely related to the type of sleep restriction that occurs
in healthy individuals who voluntarily restrict sleep.
The limitations of this study include the small sample
size that is limited to healthy nonobese men and the lack
of a control group that continued the sleep-replete condi-
tion of 10 h/night TIB from baseline through to the end of
the study. Future studies are needed to determine the
effects of sleep restriction on insulin sensitivity in other
populations, including women, obese patients, and individ-
uals with insulin resistance or diabetes. It is unlikely that
the protocol alone (in the absence of sleep restriction)
would lead to decreased insulin sensitivity because, in
other published studies, repeating these intensive glucose
metabolism test has not led to worsening of metabolic
function. Other authors, in validating different types of
metabolic challenge tests, have demonstrated the repro-
ducibility of the test results, especially for SI (50). Further-
more, the careful control of diet and exercise allowed us
to focus on effects of sleep restriction. However, sleep
restriction increases appetite and increases the desire
for high- carbohydrate/high-fat foods, so the control of
food intake may have dampened the full effects of sleep
restriction on glucose metabolism. In addition, we did
not measure circadian phase changes directly. However,
using a validated, data-based mathematical model, we
estimate a 9 min variation in circadian phase under
the experimental conditions and light levels employed
in this study (32). Thus, circadian phase changes are
unlikely to be responsible for the differences we found
in insulin sensitivity.
Insufﬁcient sleep duration (quantity) has been associ-
ated with an increased risk of obesity (3–6,51), type 2
diabetes (7–11), hypertension (12), cardiovascular disease
(13,14), metabolic syndrome (a combination of cardiovas-
cular and metabolic dysfunction) (15), and early mortality
(14,16,17,19–21,52). Our ﬁnding that reducing sleep in-
creases insulin resistance provides one possible mecha-
nism for these associations. In prospective studies,
decreases in the disposition index, the product of insulin
secretion and SI, are a strong predictor of diabetes onset
and worsening of metabolic function pre- and postdiagno-
sis (53). Our ﬁnding that sleep restriction reduces the
disposition index further supports the hypothesis that
sleep restriction contributes to the development of meta-
bolic dysregulation resulting in elevated risk for diabetes.
Future studies are needed to determine whether chronic
short sleep has detrimental effects on insulin resistance
and glucose metabolism and whether short sleep is a risk
factor for disease processes associated with insulin
resistance.
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